Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer

Trial Profile

Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 16 Aug 2017 According to an Immunomedics media release, enrollment of the first patient is expected to occur in early fourth quarter of 2017.
    • 10 May 2017 According to an Immunomedics media release, company will submit a BLA in mTNBC to the FDA during the late fourth quarter of 2017 or the first quarter of 2018.
    • 05 May 2017 According to Immunomedics media release, the company plans to enrol patient in late Q3 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top